PPHM ready to enter the The Loncar Cancer Immunotherapy Index (LCINDX)?
I bet Brad will say PPHM is in there "AFTER" PPHM makes its jump
So here we go, if Brad has not added PPHM to LCINDX yet, he will SOON and why?
Well... maybe Jill O'Donnell-Tormey knows what is coming around the corner for Peregrine Pharmaceuticals and maybe ?? hell no, I think she CERTAINLY knows by now that Peregrine is headed for big places SOON and don't forget, Dr. Rolf Brekken was invited to CRI that first year, and Dr. Jedd Wolchok was Associate Director of CRI
Chief Executive Officer of Loncar Investments, & Jill O'Donnell-Tormey, Ph.D., CEO and Director of Scientific Affairs of the Cancer Research Institute, will ring the Opening Bell.
Wait for the day that Peregrine Pharmaceuticals will be ringing that Nasdaq Bell : )
"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!